Nycomed agreed (announced 30 October 2007) to acquire Bradley Pharmaceuticals for $20.00 per share in cash, implying a fully diluted equity value of approximately $346M and a ~25% premium to Bradley's prior close. The deal strengthened Nycomed's US specialty business in dermatology and gastroenterology; it closed in February 2008.